149 related articles for article (PubMed ID: 16870769)
1. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.
Corbett AH; Patterson KB; Tien HC; Kalvass LA; Eron JJ; Ngo LT; Lim ML; Kashuba AD
Antimicrob Agents Chemother; 2006 Aug; 50(8):2756-61. PubMed ID: 16870769
[TBL] [Abstract][Full Text] [Related]
2. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.
Ford SL; Chen YC; Lou Y; Borland J; Min SS; Yuen GJ; Shelton MJ
Antimicrob Agents Chemother; 2008 Feb; 52(2):534-8. PubMed ID: 18056271
[TBL] [Abstract][Full Text] [Related]
4. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
Shelton MJ; Wire MB; Lou Y; Adamkiewicz B; Min SS
Antimicrob Agents Chemother; 2006 Mar; 50(3):928-34. PubMed ID: 16495253
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
Collier AC; Tierney C; Downey GF; Eshleman SH; Kashuba A; Klingman K; Vergis EN; Pakes GE; Rooney JF; Rinehart A; Mellors JW;
HIV Clin Trials; 2008; 9(2):91-102. PubMed ID: 18474494
[TBL] [Abstract][Full Text] [Related]
7. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
Wire MB; Ballow CH; Borland J; Shelton MJ; Lou Y; Yuen G; Lin J; Lewis EW
Antimicrob Agents Chemother; 2007 Aug; 51(8):2982-4. PubMed ID: 17517848
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
Ofotokun I; Acosta EP; Lennox JL; Pan Y; Easley KA
Pharmacotherapy; 2008 Jan; 28(1):74-81. PubMed ID: 18154477
[TBL] [Abstract][Full Text] [Related]
9. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
Cotton M; Cassim H; Pavía-Ruz N; Garges HP; Perger T; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Sievers J; Cheng K
Pediatr Infect Dis J; 2014 Jan; 33(1):57-62. PubMed ID: 23811743
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
[TBL] [Abstract][Full Text] [Related]
12. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.
Lim ML; Min SS; Eron JJ; Bertz RJ; Robinson M; Gaedigk A; Kashuba AD
J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1034-40. PubMed ID: 15247556
[TBL] [Abstract][Full Text] [Related]
14. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
Barbour AM; Gibiansky L; Wire MB
J Clin Pharmacol; 2014 Feb; 54(2):206-14. PubMed ID: 25272370
[TBL] [Abstract][Full Text] [Related]
16. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
17. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC
Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604
[TBL] [Abstract][Full Text] [Related]
18. Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.
Alexander CS; Montaner JS; Asselin JJ; Ting L; McNabb K; Harris M; Guillemi S; Harrigan PR
Ther Drug Monit; 2004 Oct; 26(5):516-23. PubMed ID: 15385834
[TBL] [Abstract][Full Text] [Related]
19. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
Cohen C; Dejesus E; Lamarca A; Young B; Yau L; Patel L; Vavro C; Wire MB; Wannamaker P; Shaefer M
HIV Clin Trials; 2010; 11(5):239-47. PubMed ID: 21126954
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir exposure with an increased dose during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli E; Hu C; Burchett SK; Holland DT; Smith E; Gaddipati S; Read JS;
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):485-91. PubMed ID: 18989231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
